Sansure Biotech (688289) Fundamentals 2026 — P/E 57.8x, Revenue Analysis | SniperIQ
Sansure Biotech (688289) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥8.7B, trading at ¥15.03 on the SHH. This SniperIQ fundamentals page covers Sansure Biotech's valuation (P/E 57.8x, P/B 1.3x), profitability (net margin 9.8%), revenue (¥1.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sansure Biotech's market cap?
Sansure Biotech (688289) has a market capitalization of approximately ¥8.7B, trading at ¥15.03 on the SHH. Market cap moves with the live share price.
What is Sansure Biotech's P/E ratio?
Sansure Biotech's trailing twelve-month P/E ratio is 57.8x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sansure Biotech?
Sansure Biotech runs a net profit margin of 9.8%, a gross margin of 73.4%, and an operating margin of 9.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sansure Biotech generate?
Sansure Biotech reported revenue of ¥1.6B for fiscal year 2025, with net income of ¥199M and earnings per share (EPS) of 0.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sansure Biotech pay a dividend?
Sansure Biotech offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sansure Biotech financially healthy?
Sansure Biotech carries a debt-to-equity ratio of 0.17x and a current ratio of 4.26x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sansure Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sansure Biotech (688289) the key facts are: market cap ¥8.7B, P/E 57.8x, revenue ¥1.6B, 52-week range 13.4-23.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sansure Biotech's full fundamentals live
Get Sansure Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.